艾伯科技(02708.HK)夥深圳時代信創就技術及產品等戰略合作
艾伯科技(02708.HK)公布,與深圳時代信創簽署戰略合作協議,根據優勢互補的原則,雙方建立信創行業的合作關係,包括但不限於在黨政、教育、金融、醫療、通訊、能源、交通、公共事業等行業市場開展業務合作。
合作內容包括技術合作、產品開發與認證合作、市場銷售合作、其它深度合作,及具體合作事宜由雙方另行商談、簽訂正式的項目合作合同。
深圳時代信創為專業IT終端先進技術及產品的設計研發公司,提供筆記本和其他電子產品的先進技術和產品服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.